Treatment and rehabilitation of Long COVID: A scope of the literature. Update April 2024

Gary Austin Raine; Claire Louise Khouja; Helen Fulbright; Katy Sutcliffe; Amanda Jayne Sowden

Treatment and rehabilitation of Long COVID: A scope of the literature. Update April 2024

Gary Austin Raine, Claire Louise Khouja, Helen Fulbright, Katy Sutcliffe, Amanda Jayne Sowden

Centre for Reviews and Dissemination

Research output: Book/Report › Commissioned report

Abstract

We identified 15 randomised controlled trials published between December 2023 and March 2024 that were focused on Long COVID treatment or rehabilitation. Across our eight reports produced to date, we have identified and assessed 121 trials published between January 2022 and March 2024.
• Seven of the 15 trials focused on treating generalised or multiple symptoms of Long COVID/Post COVID condition. Three trials evaluated treatments for fatigue, one of which also focused on individuals with other neuropsychiatric sequalae. Two trials had a focus on respiratory or cardiovascular function or physical fitness. Two other trials focused on persistent problems with the sense of smell or taste (olfactory/gustatory dysfunction). One trial focused on people with decreased functioning and participation in daily life following COVID-19.
• Two trials were rated positively for 12 out of the 13 quality criteria that we assessed. Two trials met ten criteria and 11 gained a positive rating for between six and nine criteria.

Original language	English
Place of Publication	London
Publisher	EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.
Commissioning body	NIHR Policy Research Programme
Number of pages	28
ISBN (Print)	978-1-911605-55-3
Publication status	Published - 6 Jun 2024

Bibliographical note

Access to Document

LC_treatment8_April24_060624-LO
© Copyright 2024. Authors of the systematic reviews on the EPPI Centre website (http://eppi.ioe.ac.uk/) hold the copyright for the text of their reviews. The EPPI Centre owns the copyright for all material on the website it has developed, including the contents of the databases, manuals, and keywording and data-extraction systems. The centre and authors give permission for users of the site to display and print the contents of the site for their own non-commercial use, providing that the materials are not modified, copyright and other proprietary notices contained in the materials are retained, and the source of the material is cited clearly following the citation details provided. Otherwise, users are not permitted to duplicate, reproduce, re-publish, distribute, or store material from this website without express written permission.
Final published version, 1.05 MBLicence: CC BY-NC

Cite this

@book{543a9ced06ea4eb9b16773861462efc1,

title = "Treatment and rehabilitation of Long COVID: A scope of the literature. Update April 2024",

abstract = "We identified 15 randomised controlled trials published between December 2023 and March 2024 that were focused on Long COVID treatment or rehabilitation. Across our eight reports produced to date, we have identified and assessed 121 trials published between January 2022 and March 2024.• Seven of the 15 trials focused on treating generalised or multiple symptoms of Long COVID/Post COVID condition. Three trials evaluated treatments for fatigue, one of which also focused on individuals with other neuropsychiatric sequalae. Two trials had a focus on respiratory or cardiovascular function or physical fitness. Two other trials focused on persistent problems with the sense of smell or taste (olfactory/gustatory dysfunction). One trial focused on people with decreased functioning and participation in daily life following COVID-19.• Two trials were rated positively for 12 out of the 13 quality criteria that we assessed. Two trials met ten criteria and 11 gained a positive rating for between six and nine criteria.",

author = "Raine, {Gary Austin} and Khouja, {Claire Louise} and Helen Fulbright and Katy Sutcliffe and Sowden, {Amanda Jayne}",

year = "2024",

month = jun,

day = "6",

language = "English",

isbn = "978-1-911605-55-3",

publisher = "EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.",

}

TY - BOOK

T1 - Treatment and rehabilitation of Long COVID

T2 - A scope of the literature. Update April 2024

AU - Raine, Gary Austin

AU - Khouja, Claire Louise

AU - Fulbright, Helen

AU - Sutcliffe, Katy

AU - Sowden, Amanda Jayne

PY - 2024/6/6

Y1 - 2024/6/6

N2 - We identified 15 randomised controlled trials published between December 2023 and March 2024 that were focused on Long COVID treatment or rehabilitation. Across our eight reports produced to date, we have identified and assessed 121 trials published between January 2022 and March 2024.• Seven of the 15 trials focused on treating generalised or multiple symptoms of Long COVID/Post COVID condition. Three trials evaluated treatments for fatigue, one of which also focused on individuals with other neuropsychiatric sequalae. Two trials had a focus on respiratory or cardiovascular function or physical fitness. Two other trials focused on persistent problems with the sense of smell or taste (olfactory/gustatory dysfunction). One trial focused on people with decreased functioning and participation in daily life following COVID-19.• Two trials were rated positively for 12 out of the 13 quality criteria that we assessed. Two trials met ten criteria and 11 gained a positive rating for between six and nine criteria.

AB - We identified 15 randomised controlled trials published between December 2023 and March 2024 that were focused on Long COVID treatment or rehabilitation. Across our eight reports produced to date, we have identified and assessed 121 trials published between January 2022 and March 2024.• Seven of the 15 trials focused on treating generalised or multiple symptoms of Long COVID/Post COVID condition. Three trials evaluated treatments for fatigue, one of which also focused on individuals with other neuropsychiatric sequalae. Two trials had a focus on respiratory or cardiovascular function or physical fitness. Two other trials focused on persistent problems with the sense of smell or taste (olfactory/gustatory dysfunction). One trial focused on people with decreased functioning and participation in daily life following COVID-19.• Two trials were rated positively for 12 out of the 13 quality criteria that we assessed. Two trials met ten criteria and 11 gained a positive rating for between six and nine criteria.

M3 - Commissioned report

SN - 978-1-911605-55-3

BT - Treatment and rehabilitation of Long COVID

PB - EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.

CY - London

ER -